Johnson & Johnson has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions.
The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer, of which new diagnostics are projected to reach 1.7 million globally by 2030. Given the existing unmet need, this once-daily therapy has the potential to transform patient outcomes with its novel precision cancer cell-killing approach that can overcome mechanisms of resistance to treatment. The acquisition also includes several earlier candidates for breast, lung, and multiple other tumor types. Halda’s pipeline and platform may also enable the creation of novel targeted therapies beyond oncology.
“This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We look forward to combining Halda’s pipeline, platform, and people with our world-class R&D, commercial, and manufacturing capabilities and advancing our goal of bringing these therapies to patients around the world.”
The planned acquisition underscores Johnson & Johnson’s longstanding commitment to prostate cancer and its industry-leading oncology portfolio, adding new therapies with novel and complementary mechanisms of action. Halda’s pipeline of differentiated assets, if successful, will provide critical new options for patients.
About the Acquisition Agreement
Under the terms of the agreement, Johnson & Johnson will acquire Halda. The transaction will be accounted for as a business combination and is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. The Company expects dilution in 2026 of $0.15 to Adjusted Earnings Per Share (EPS) due to short-term financing and a non-recurring charge related to the equity awards for Halda employees upon closing. Johnson & Johnson will provide commentary on full-year 2026 guidance during the fourth quarter earnings call on Wednesday, January 21, 2026.
Source: chemanager-online.com
The strategic collaboration will see Merck offer Valo over a potential $3bn in upfront and milestone payments, as well as R&D funding and royalties from any products that come from the work. In return, the German drugmaker will use Valo’s AI human casual biology and discovery platforms to find new disease targets and create preclinical compounds.
GE HealthCare plans to pay $2.3 billion in cash to acquire imaging software developer Intelerad, toward the goal of building a cloud-first diagnostic ecosystem that can tap into ambulatory, teleradiology and hospital settings.
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire obesity biotech Metsera. After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn offer.
